Impact of Immunotherapy on Real-World Survival Outcomes in
Metastatic Renal Cell Carcinoma

J 2023

Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma

POPRACH, Alexandr; Igor KISS; Michal STANÍK; Tamara BARUSOVA; Lenka POSPISILOVA et al.

Základní údaje

Originální název

Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma

Autoři

Vydání

Targeted Oncology, Dordrecht, Springer, 2023, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.400

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00134702

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Renal Cell Carcinoma; Immunotherapy

Štítky

14110811, 14110813, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 1. 2024 12:17, Mgr. Tereza Miškechová

Anotace

V originále

Background Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. Objective The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. Methods RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. Results The median overall survival from the initiation of first-line treatment was 24.5 months versus notreached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. Conclusion In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.

Návaznosti

NU21-03-00539, projekt VaV

Název: Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu

Investor: Ministerstvo zdravotnictví ČR, Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu, Podprogram 1 - standardní

Citovat

POPRACH, Alexandr; Igor KISS; Michal STANÍK; Tamara BARUSOVA; Lenka POSPISILOVA; Ondrej FIALA; Jindrich KOPECKY; Igor RICHTER; Bohuslav MELICHAR; Hana STUDENTOVA; Radek LAKOMÝ; Miloš HOLÁNEK; Aneta ROZSYPALOVA; Anezka ZEMANKOVA; Marek SVOBODA a Tomas BUCHLER. Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma. Targeted Oncology. Dordrecht: Springer, 2023, roč. 18, November 2023, s. 893-903. ISSN 1776-2596. Dostupné z: https://doi.org/10.1007/s11523-023-01013-0.

@article{2368103,
   author = {Poprach, Alexandr and Kiss, Igor and Staník, Michal and Barusova, Tamara and Pospisilova, Lenka and Fiala, Ondrej and Kopecky, Jindrich and Richter, Igor and Melichar, Bohuslav and Studentova, Hana and Lakomý, Radek and Holánek, Miloš and Rozsypalova, Aneta and Zemankova, Anezka and Svoboda, Marek and Buchler, Tomas},
   article_location = {Dordrecht},
   article_number = {November 2023},
   doi = {https://doi.org/10.1007/s11523-023-01013-0},
   keywords = {Renal Cell Carcinoma; Immunotherapy},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma},
   url = {https://link.springer.com/article/10.1007/s11523-023-01013-0},
   volume = {18},
   year = {2023}
}

TY  - JOUR
ID  - 2368103
AU  - Poprach, Alexandr - Kiss, Igor - Staník, Michal - Barusova, Tamara - Pospisilova, Lenka - Fiala, Ondrej - Kopecky, Jindrich - Richter, Igor - Melichar, Bohuslav - Studentova, Hana - Lakomý, Radek - Holánek, Miloš - Rozsypalova, Aneta - Zemankova, Anezka - Svoboda, Marek - Buchler, Tomas
PY  - 2023
TI  - Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
JF  - Targeted Oncology
VL  - 18
IS  - November 2023
SP  - 893-903
EP  - 893-903
PB  - Springer
SN  - 17762596
KW  - Renal Cell Carcinoma
KW  - Immunotherapy
UR  - https://link.springer.com/article/10.1007/s11523-023-01013-0
N2  - Background Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. Objective The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. Methods RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. Results The median overall survival from the initiation of first-line treatment was 24.5 months versus notreached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. Conclusion In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.
ER  -

POPRACH, Alexandr; Igor KISS; Michal STANÍK; Tamara BARUSOVA; Lenka POSPISILOVA; Ondrej FIALA; Jindrich KOPECKY; Igor RICHTER; Bohuslav MELICHAR; Hana STUDENTOVA; Radek LAKOMÝ; Miloš HOLÁNEK; Aneta ROZSYPALOVA; Anezka ZEMANKOVA; Marek SVOBODA a Tomas BUCHLER. Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma. \textit{Targeted Oncology}. Dordrecht: Springer, 2023, roč.~18, November 2023, s.~893-903. ISSN~1776-2596. Dostupné z: https://doi.org/10.1007/s11523-023-01013-0.

Přehled o publikaci